title: Regulated norepinephrine transporter interaction with the neurokinin-1 receptor establishes transporter subcellular localization.
abstract: Neurokinin-1 receptor (NK1R) mediates down-regulation of human norepinephrine (NE) transporter (hNET) via protein kinase C (PKC). However, native NET regulation by NK1R and the mechanism by which NK1R targets NET among other potential effectors are unknown. Effect of NK1R activation on native NET regulation and NET/NK1R interaction were studied using rat brain synaptosomes expressing native NET and NK1R as well as human placental trophoblast (HTR) cells coexpressing WT-hNET or NK1R/PKC-resistant hNET-T258A,S259A double mutant (NET-DM) and hNK1R. The selective NK1R agonist, GR73632, and Substance-P (SP) inhibited NE transport and reduced plasma membrane expression of NET and NK1R. Pretreatment with the NK1R antagonist, EMEND (aprepitant) prevented these NK1R-mediated effects. Immunoprecipitation experiments showed that NET forms stable complexes with NK1R. In HTR cells, combined biotinylation and immunoprecipitation studies revealed plasma membrane localization of NET·NK1R complexes. Receptor activation resulted in the internalization of NET·NK1R complexes. Lipid raft and immunoprecipitation analyses revealed the presence of NET·NK1R complexes exclusively in non-raft membrane fractions under basal/unstimulated conditions. However, NK1R activation led to translocation of NET·NK1R complexes to raft-rich membrane fractions. Importantly, PKCα was found in association with raft-localized NET following SP treatment. Similar to WT-NET, PKC-resistant NET-DM was found in association with NK1R exclusively in non-raft fractions. However, SP treatment failed to translocate NET-DM·NK1R complexes from non-raft fractions to raft fractions. Collectively, these results suggest that NK1R forms physical complexes with NET and that the receptor-mediated Thr(258) + Ser(259) motif-dependent translocation of NET·NK1R complexes into raft-rich microdomains facilitates NET/NK1R interaction with PKCα to coordinate spatially restricted NET regulation.
authors: From the Department of Neurosciences, Division of Neuroscience Research, Medical University of South Carolina, Charleston, South Carolina 29425 and.
authors: Obulakshmi
authors: O
authors: Arapulisamy
authors: Padmanabhan
authors: P
authors: Mannangatti
authors: Lankupalle D
authors: LD
authors: Jayanthi
mesh_terms: D000818:Animals; D015536:Down-Regulation / Q000187:drug effects; D004705:Endocytosis / Q000187:drug effects; D006801:Humans; D008297:Male; D021962:Membrane Microdomains / Q000187:drug effects / Q000378:metabolism; D009638:Norepinephrine / Q000378:metabolism; D050484:Norepinephrine Plasma Membrane Transport Proteins / Q000378:metabolism*; D010446:Peptide Fragments / Q000494:pharmacology; D011485:Protein Binding / Q000187:drug effects; D021381:Protein Transport / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D018040:Receptors, Neurokinin-1 / Q000378:metabolism*; D013347:Subcellular Fractions / Q000187:drug effects / Q000378:metabolism; D013373:Substance P / Q000031:analogs & derivatives / Q000494:pharmacology
chemical_list: D050484:Norepinephrine Plasma Membrane Transport Proteins; D010446:Peptide Fragments; D018040:Receptors, Neurokinin-1; C068032:GR 73632; D013373:Substance P; D009638:Norepinephrine
keywords: Catecholamines; G Protein-coupled Receptors (GPCR); Internalization; Lipid Rafts; Monoamine Transporters; Plasma Membrane; Protein-protein Interactions; Regulation
references: J Biol Chem. 2011 Jun 10;286(23):20239-50
references: 21498515
references: J Cell Biol. 2003 Sep 1;162(5):773-9
references: 12952931
references: J Biol Chem. 2005 Feb 25;280(8):7135-46
references: 15590676
references: Behav Pharmacol. 2001 Nov;12(6-7):497-508
references: 11742144
references: J Neurochem. 2001 Nov;79(4):787-95
references: 11723171
references: Mol Pharmacol. 2011 Sep;80(3):458-65
references: 21705486
references: Future Neurol. 2010 Jan 1;5(1):123
references: 20174452
references: Cell Signal. 2009 Jan;21(1):87-94
references: 18929645
references: Neurochem Int. 2010 Dec;57(8):923-34
references: 20933035
references: Biol Psychiatry. 1999 Nov 1;46(9):1124-30
references: 10560019
references: Pharmacol Ther. 2001 Oct;92(1):21-55
references: 11750035
references: Biochemistry. 2011 Aug 30;50(34):7295-310
references: 21797260
references: Eur J Neurosci. 2007 Sep;26(6):1509-20
references: 17714497
references: J Neurosci. 2003 Mar 1;23(5):1697-709
references: 12629174
references: J Biol Chem. 2004 Apr 30;279(18):19315-26
references: 14976208
references: Trends Pharmacol Sci. 1991 Sep;12(9):334-7
references: 1659001
references: J Pharmacol Exp Ther. 1998 Nov;287(2):733-43
references: 9808704
references: Br J Pharmacol. 2002 Apr;135(8):1927-34
references: 11959795
references: Mol Cell Neurosci. 2007 Feb;34(2):251-60
references: 17188889
references: BMC Neurosci. 2009 Jun 23;10:65
references: 19545450
references: Biochem Biophys Res Commun. 2005 Aug 5;333(3):671-8
references: 15963952
references: J Neurochem. 2008 Jun;105(5):1683-99
references: 18248623
references: Neuron. 2001 Apr;30(1):121-34
references: 11343649
references: Handb Exp Pharmacol. 2006;(175):327-71
references: 16722243
references: Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2138-43
references: 16461466
references: PLoS One. 2013;8(3):e59788
references: 23555781
references: Br J Pharmacol. 2012 Sep;167(2):256-78
references: 22519513
references: EMBO J. 2007 Apr 18;26(8):2127-36
references: 17380124
references: Br J Pharmacol. 1971 Apr;41(4):571-91
references: 4397129
references: J Biol Chem. 2005 Mar 25;280(12):10914-9
references: 15647254
references: Mol Pharmacol. 2012 Jan;81(1):73-85
references: 21992875
references: J Neurosci. 2000 Oct 15;20(20):7571-8
references: 11027216
references: J Biol Chem. 2006 Aug 18;281(33):23326-40
references: 16740633
references: Mol Pharmacol. 2007 May;71(5):1222-32
references: 17267664
references: Mol Cell Neurosci. 2009 Sep;42(1):56-65
references: 19463951
references: J Neurochem. 2010 Oct;115(1):23-35
references: 20626559
references: Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):1029-34
references: 11805341
references: Neurosci Res. 2002 Sep;44(1):71-81
references: 12204295
references: J Pharmacol Exp Ther. 2008 Apr;325(1):293-301
references: 18198344
references: Naunyn Schmiedebergs Arch Pharmacol. 1989 Nov;340(5):502-8
references: 2559332
references: J Psychopharmacol. 2010 Jan;24(1):27-38
references: 19204064
references: Am J Physiol Cell Physiol. 2008 Mar;294(3):C683-92
references: 18160487
references: Eur J Neurosci. 2007 Feb;25(4):1195-204
references: 17331215
references: Neuropharmacology. 2009 Dec;57(7-8):627-35
references: 19748515
references: J Biol Chem. 2001 Jul 6;276(27):25427-37
references: 11306580
references: Nat Rev Mol Cell Biol. 2000 Oct;1(1):31-9
references: 11413487
references: Mol Brain. 2009 Aug 05;2:26
references: 19656393
references: J Biol Chem. 2003 Feb 14;278(7):4990-5000
references: 12464618
references: Br J Pharmacol. 1996 Sep;119(2):315-20
references: 8886415
references: J Neurosci. 2008 Jun 18;28(25):6516-25
references: 18562623
references: J Biol Chem. 1998 Jan 23;273(4):2458-66
references: 9442097
references: Am J Physiol Cell Physiol. 2011 Oct;301(4):C780-91
references: 21795521
references: Eur Neuropsychopharmacol. 2008 Oct;18(10):729-50
references: 18657401
references: Neuropharmacology. 2000 Jun 8;39(8):1413-21
references: 10818257